<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03214250</url>
  </required_header>
  <id_info>
    <org_study_id>PICI0002</org_study_id>
    <secondary_id>UPCC 11217</secondary_id>
    <nct_id>NCT03214250</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parker Institute for Cancer Immunotherapy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apexigen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research Institute, New York City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Parker Institute for Cancer Immunotherapy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purposes of this study are to learn how effective the study drug combinations are in
      treating patients with metastatic pancreatic adenocarcinoma. The drug combinations are
      APX005M+Nivolumab+Gemcitabine+nab-Paclitaxel, or APX005M+Gemcitabine+nab-Paclitaxel.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)</measure>
    <time_frame>up to 6 month</time_frame>
    <description>Phase 1b Primary Safety Outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS) defined as the time from initiation of study therapy to date of death due to any cause or date of most recent subject contact.</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Phase 2 Primary Efficacy Outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) as determined by RECIST criteria</measure>
    <time_frame>up to 6 month</time_frame>
    <description>Phase 1b and Phase 2 Secondary Efficacy Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) defined as time from first documentation of response (complete response [CR] or partial response [PR]) to first documentation of progressive disease</measure>
    <time_frame>up to 6 month</time_frame>
    <description>Phase 1b and Phase 2 Secondary Efficacy Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) is defined as the proportion of subjects who achieve a CR or PR or SD</measure>
    <time_frame>up to 6 month</time_frame>
    <description>Phase 2 Secondary Efficacy Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) defined as the time from initiation of study therapy to date of first documented progression of disease, date of death due to any cause or date of most recent subject contact which documented progression free status</measure>
    <time_frame>up to 6 month</time_frame>
    <description>Phase 2 Secondary Efficacy Outcome</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Gem/NP/nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine+Nab-Paclitaxel+nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem/NP/APX005M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine+Nab-Paclitaxel+APX005M</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem/NP/nivolumab/APX005M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine+Nab-Paclitaxel+nivolumab+APX005M</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX005M</intervention_name>
    <description>Administer intravenously once every 28-day Cycle</description>
    <arm_group_label>Gem/NP/APX005M</arm_group_label>
    <arm_group_label>Gem/NP/nivolumab/APX005M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Administer intravenously twice every 28-day cycle</description>
    <arm_group_label>Gem/NP/nivolumab</arm_group_label>
    <arm_group_label>Gem/NP/nivolumab/APX005M</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Administer intravenously on 3 times every 28-day cycle</description>
    <arm_group_label>Gem/NP/nivolumab</arm_group_label>
    <arm_group_label>Gem/NP/APX005M</arm_group_label>
    <arm_group_label>Gem/NP/nivolumab/APX005M</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administer intravenously 3 times every 28-day cycle</description>
    <arm_group_label>Gem/NP/nivolumab</arm_group_label>
    <arm_group_label>Gem/NP/APX005M</arm_group_label>
    <arm_group_label>Gem/NP/nivolumab/APX005M</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has histologically or cytologically documented diagnosis of pancreatic
             adenocarcinoma with metastatic disease. Locally advanced subjects are not eligible.

          2. Subject must have measureable disease by RECIST 1.1.

          3. Subjects must be age 18 years or older.

          4. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0 or 1.

          5. Subjects must have the following laboratory values at screening within 2 weeks of the
             first dose of investigational agents:

               -  Absolute neutrophil count (ANC) ≥1.5 x 109/L (in absence of growth factor
                  support)

               -  Platelet count ≥150 x 109/L

               -  Hemoglobin ≥9 g/dL(without transfusion support)

               -  Serum creatinine ≤1.5 mg/dL, and creatinine clearance ≥ 50 ml/min as measured by
                  Cockcroft and Gault formula

               -  Aspartate aminotransferase (AST) and ALT ≤2.5 x upper limit of normal (ULN)

               -  Total bilirubin ≤1.5 x ULN, except in subjects with documented Gilbert's
                  Syndrome, who must have a total bilirubin ≤3 x ULN

          6. Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum or
             urine) within the 7 days prior to study drug administration, and within the 3 days
             before the first study drug administration, or a negative pregnancy test within the 24
             hours before the first study drug administration.

          7. WOCBP and male subjects who are sexually active with WOCBP must agree to use 2 highly
             effective methods of contraception (including a physical barrier) before the first
             dose of study drugs, during the study, and for 5 months for women and 7 months for men
             following the last dose of study drug.

          8. Subjects must have the ability to understand and willingness to sign a written
             informed consent document.

        Exclusion Criteria:

          1. Subject must not have received any prior treatment, including chemotherapy, biological
             therapy, or targeted therapy for metastatic pancreatic adenocarcinoma, with the
             following exceptions and notes:

               1. Subjects who have received prior adjuvant therapy for pancreatic adenocarcinoma
                  are eligible if neoadjuvant and adjuvant therapy (including chemotherapy and/or
                  radiotherapy) was fully completed more than 4 months before the start of study
                  treatment. In this case, prior Gem and/or NP is allowable

               2. Prior resection surgery is allowable.

               3. Patients initially diagnosed with locally advanced pancreatic cancer who have
                  undergone chemotherapy then resection and were with no evidence of disease are
                  eligible if metastatic relapse of disease has occurred and if the last dose of
                  chemotherapy was more than 4 months before the data of study entry.

          2. Subjects must not have another active invasive malignancy, with the following
             exceptions and notes:

               1. History of a non-invasive malignancy, such as cervical cancer in situ,
                  non-melanomatous carcinoma of the skin, in situ melanoma, or ductal carcinoma in
                  situ of the breast, is allowed.

               2. History of malignancy that is in complete remission after treatment with curative
                  intent is allowed.

               3. No current or history of a hematologic malignancy is allowed, including subjects
                  who have undergone a bone marrow transplant.

          3. History of clinically significant sensitivity or allergy to monoclonal antibodies,
             their excipients, or intravenous gamma globulin

          4. Previous exposure to CD40, PD-1, PD-L1, CTLA-4 antibodies or any other
             immunomodulatory agent

          5. History of (non-infectious) pneumonitis that required corticosteroids or current
             pneumonitis, or history of interstitial lung disease

          6. Subjects must not have a known or suspected history of an autoimmune disorder,
             including but not limited to inflammatory bowel disease, celiac disease, Wegner
             syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis,
             or autoimmune hepatitis, within 3 years of the first dose of investigational agent,
             except for the following.

             a. Subjects with Type 1 diabetes mellitus, hypothyroidism only requiring hormone
             replacement, skin disorders such as vitiligo, or alopecia not requiring systemic
             therapy, or conditions not expected to recur in the absence of an external trigger are
             eligible.

          7. Subjects must not have an uncontrolled intercurrent illness, including an ongoing or
             active infection, current pneumonitis, symptomatic congestive heart failure (New York
             Heart Association class III or IV), unstable angina, uncontrolled hypertension,
             cardiac arrhythmia, interstitial lung disease, active coagulopathy, or uncontrolled
             diabetes.

          8. Subjects must not have a history of myocardial infarction within 6 months or a history
             of arterial thromboembolic event within 3 months of the first dose of investigational
             agent.

          9. Subjects must not have a history of human immunodeficiency virus, hepatitis B, or
             hepatitis C, except for the following:

               1. subjects with anti-hepatitis B core antibody but with undetectable HBV DNA and
                  negative for HBsAg

               2. subjects with resolved or treated HCV (i.e. HCV antibody positive but
                  undetectable HCV RNA)

         10. Subjects must not have a history of primary immunodeficiency.

         11. Subjects must not receive concurrent or prior use of an immunosuppressive agent within
             14 days of the first dose of investigational agent, with the following exceptions and
             notes:

               1. Systemic steroids at physiologic doses (equivalent to dose of oral prednisone 10
                  mg) are permitted. Steroids as anti-emetics for chemotherapy are not allowed.

               2. Intranasal, inhaled, topical, intra-articular, and ocular corticosteroids with
                  minimal systemic absorption are permitted.

               3. Subjects with a condition with anticipated use of systemic steroids above the
                  equivalent of 10 mg prednisone are excluded.

         12. Subjects must not have a history of clinically manifested central nervous system (CNS)
             metastases.

             a. Subjects with known or suspected leptomeningeal disease or cord compression are not
             eligible.

         13. Subjects must not have had major surgery as determined by the PI within 4 weeks before
             the first dose of investigational agent.

         14. Subjects must not have received another investigational agent within the shorter of 4
             weeks or 5 half-lives before the first dose of investigational agent.

         15. Subjects must not have received a live attenuated vaccine within 28 days before the
             first dose of investigational agent, and subjects, if enrolled, should not receive
             live vaccines during the study or for 180 days after the last dose of investigational
             agent.

         16. Females who are pregnant or lactating or who intend to become pregnant during
             participation in the study are not eligible to participate.

         17. Subjects who are of reproductive potential who refuse to use effective methods of
             birth control during the course of participation of the study and within 5 month for
             women and 7 months for men of the last dose of investigational agent are ineligible to
             participate in the study.

         18. Subjects who have any clinically significant psychiatric, social, or medical condition
             that, in the opinion of the investigator, could increase the subject's risk, interfere
             with protocol adherence, or affect the subject's ability to give informed consent are
             ineligible to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert H Vonderheide, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the site directly. If there is no contact info,</last_name>
    <phone>please email</phone>
    <email>Clinical.trials@parkerici.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Yonemoto</last_name>
      <phone>310-582-4069</phone>
      <email>lyonemoto@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Zev A Wainberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie McCluggage</last_name>
      <phone>415-514-8133</phone>
      <email>Julie.McCluggage@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew H Ko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanford Cancer Clinical Trials Office, Outreach</last_name>
      <phone>650-498-7061</phone>
      <email>ccto-office@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>George Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Brenner, RN</last_name>
      <email>brennerr@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Eileen O'Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Redlinger</last_name>
      <phone>215-220-9693</phone>
      <email>Colleen.Redlinger@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Mark O'Hara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Trevino, RN</last_name>
      <phone>713-792-0622</phone>
      <email>tltrevino@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Gauri Varadhachary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155. Erratum in: Cancer Res. 2014 Jul 15;74(14):4006.</citation>
    <PMID>24840647</PMID>
  </reference>
  <reference>
    <citation>Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.</citation>
    <PMID>24131140</PMID>
  </reference>
  <reference>
    <citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. Review.</citation>
    <PMID>22437870</PMID>
  </reference>
  <reference>
    <citation>Bauer C, Kühnemuth B, Duewell P, Ormanns S, Gress T, Schnurr M. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Lett. 2016 Oct 10;381(1):259-68. doi: 10.1016/j.canlet.2016.02.057. Epub 2016 Mar 8. Review.</citation>
    <PMID>26968250</PMID>
  </reference>
  <reference>
    <citation>Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW. The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol. 2012 Aug;31(4):246-66. doi: 10.3109/08830185.2012.698338. Review.</citation>
    <PMID>22804570</PMID>
  </reference>
  <reference>
    <citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.</citation>
    <PMID>22658127</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>APX005M</keyword>
  <keyword>previously untreated metastatic pancreatic adenocarcinoma</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>nab-Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

